Century Therapeutics, Inc. (IPSC) News
Track canonical SquawkNews coverage tagged to IPSC, Century Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Century Therapeutics appoints Joseph Truitt to board
Century Therapeutics appointed Joseph Truitt to its board as a Class I director, effective September 9, 2026. He was also named to the Compensation Committee.
EQUITY | Sep 09, 2026, 08:16 PM UTC
L
Century Therapeutics appoints Joseph Truitt to its board
Century Therapeutics, Inc. announced the appointment of Joseph Truitt to its board of directors. The company said it develops iPSC-derived cell therapies for autoimmune diseases including type 1 diabetes and cancer.
EQUITY | Sep 09, 2026, 08:11 PM UTC
L
Century Therapeutics appoints Joseph Truitt to board of directors
EQUITY | Sep 09, 2026, 08:05 PM UTC
L
Century Therapeutics appoints Joseph Truitt to board
EQUITY | Sep 09, 2026, 08:05 PM UTC
L
IPSC Reports Q2 2026 Financial Results
IPSC reports second quarter 2026 financial results and business updates
EARNINGS | Aug 12, 2026, 12:01 PM UTC
M
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises In c (NASDAQ: APOG ) rose sharply after the company reported better-than-expected first-quarter financ
EARNINGS | Jun 26, 2026, 01:39 PM UTC